What $2M of grant money actually costs you
Non-dilutive does not mean free. The real price is time, scope commitment, and reporting — and it is still almost always cheaper than the equity alternative.
"Non-dilutive" is a great word. It is also slightly misleading, because it describes only the thing you do not pay.
If you are deciding whether to chase federal funding at all, price it honestly.
What it actually costs
Time, concentrated in the wrong people. A serious application takes weeks, and most of it must come from whoever understands the science best — usually your most expensive and least replaceable person. That is the real line item.
Scope commitment. You are proposing specific aims and you will be expected to pursue them. If your platform is likely to pivot in the next year, a grant is a commitment to a direction as much as a cheque.
Administrative overhead. Registrations, reporting, audit expectations, and compliance obligations that scale with the size and type of award. This is manageable, but it is not zero, and it lands on a team that has no one whose job it is.
Latency. Submission to money in the bank runs months, not weeks. Grant funding is not bridge financing and should never be modelled as such.
What it does not cost
Equity. And that is the entire argument.
Money raised on a priced round is the most expensive capital an early company ever takes, because you are selling the part of the company that is worth the most later. A grant that funds twelve months of preclinical work is twelve months you did not sell.
There is a second-order effect that matters just as much: the work you fund non-dilutively de-risks the asset, and you raise your next round against a better story. Investors do not merely tolerate grant funding — a competitive federal award is third-party technical validation from reviewers with no financial interest in flattering you.
How to decide
A rough test that holds up:
- Is the work you would propose work you were going to do anyway? If yes, the
scope commitment costs you nothing.
- Do you have someone who can write it without stopping everything else? If
the honest answer is no, the time cost is higher than it looks.
- Is your runway longer than the award timeline? Grants reward companies that
can wait. If you need money this quarter, this is the wrong instrument.
If those three land well, the arithmetic is not close. Federal money is the cheapest capital in biotech and it is not a near-run thing.
The reason founders miss it is not that the maths is hard. It is that finding which programmes fit, confirming eligibility, and tracking deadlines across ten agencies is a job, and nobody on an early team has it.
That is the job SixthGrant does.
Stop finding out too late.
SixthGrant reads every federal solicitation daily, checks each one against your company, and tells you what changed.
See what it costs →